Loading...
Loading...
UTHR| Name | Value |
|---|---|
| Revenues | 714.9M |
| Cost of Revenue | 77.8M |
| Gross Profit | 637.1M |
| Operating Expense | 317.2M |
| Operating I/L | 319.9M |
| Other Income/Expense | 35.4M |
| Interest Income | 46.2M |
| Pretax | 355.3M |
| Income Tax Expense | 77.2M |
| Net Income/Loss | 278.1M |
United Therapeutics Corporation is a biotechnology company specializing in the development and commercialization of therapies for patients with chronic and life-threatening diseases. Its products include Remodulin, Tyvaso, Orenitram, Unituxin, and Adcirca, targeting conditions such as pulmonary arterial hypertension and high-risk neuroblastoma. The company also focuses on developing new formulations and delivery systems for its existing products, as well as gene therapy products like Aurora-GT. United Therapeutics generates revenue through the sales of its commercial therapies and through licensing and collaboration agreements with other companies for the development and commercialization of new products.
